annb0t
Top 20
ResMed Inc.'s RMD adjusted earnings per share (EPS) in the fourth quarter of fiscal 2022 were $1.49, up 10.4% year over year. The metric also surpassed the Zacks Consensus Estimate by 0.7%.
The adjustments include certain non-recurring expenses/benefits like amortization of acquired intangibles and restructuring costs, among others.
Full-year adjusted EPS was $5.79, up 8.6%. The metric surpassed the Zacks Consensus Estimate by 0.7%.
GAAP EPS in the reported quarter was $1.33, similar to the y...
>>> Read more: ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
The adjustments include certain non-recurring expenses/benefits like amortization of acquired intangibles and restructuring costs, among others.
Full-year adjusted EPS was $5.79, up 8.6%. The metric surpassed the Zacks Consensus Estimate by 0.7%.
GAAP EPS in the reported quarter was $1.33, similar to the y...
>>> Read more: ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
